Barbara Helen Rosario
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barbara Helen Rosario has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Vivian Cantiller Barrera
Department of Geriatric Medicine, Changi General Hospital, Singapore
4 shared publicationsClara Yi-En Seah
3 shared publicationsAileen Lim
Health Systems Intelligence, Changi General Hospital, Singapore
2 shared publications- Bharathi Balasundaram
Changi General Hospital
2 shared publications Candelyn Yu Pong
Health Services and Systems Research, Duke-NUS Medical School, Singapore
2 shared publicationsColin Yeo
2 shared publications
Latest Publications
- 25 September 2026
- Published by Wolters Kluwer Health in Singapore Medical Journal
Hospitalisation experience and frailty prevention in older patients: a qualitative study
Introduction: Frailty is associated with an increased risk of falls, delirium, disability, hospitalisation, readmission and nursing home admission. This study aimed to explore the perception of frailty, frailty prevention strategies and hospitalisation experience among frail inpatients and their caregivers. Methods: This qualitative study included frail hospitalised patients in a tertiary hospital and their primary family caregivers who provided physical and social support daily. Face-to-face interviews were conducted from May 2023 to November 2023. Results: Ten patients (median age 74.3 years) and 11 caregivers (median age 56.0 years) were interviewed. Five themes emerged. We found a lack of understanding and awareness of frailty as well as barriers to preventing it. Due to the decreasing ability to perform daily activities, patients were not actively engaging in preventive activities and seldom used community services owing to inconvenience, financial concerns and a lack of trust in the external party. The majority of patients faced self-care difficulties during hospital stay. Conclusion: We identified gaps in frailty awareness and specific barriers to and facilitators of frailty prevention. The findings from this study could guide the development and implementation of frailty interventions.
- 25 September 2026
- Published by Wolters Kluwer Health in Singapore Medical Journal
Hospitalisation experience and frailty prevention in older patients: a qualitative study
Introduction: Frailty is associated with an increased risk of falls, delirium, disability, hospitalisation, readmission and nursing home admission. This study aimed to explore the perception of frailty, frailty prevention strategies and hospitalisation experience among frail inpatients and their caregivers. Methods: This qualitative study included frail hospitalised patients in a tertiary hospital and their primary family caregivers who provided physical and social support daily. Face-to-face interviews were conducted from May 2023 to November 2023. Results: Ten patients (median age 74.3 years) and 11 caregivers (median age 56.0 years) were interviewed. Five themes emerged. We found a lack of understanding and awareness of frailty as well as barriers to preventing it. Due to the decreasing ability to perform daily activities, patients were not actively engaging in preventive activities and seldom used community services owing to inconvenience, financial concerns and a lack of trust in the external party. The majority of patients faced self-care difficulties during hospital stay. Conclusion: We identified gaps in frailty awareness and specific barriers to and facilitators of frailty prevention. The findings from this study could guide the development and implementation of frailty interventions.
- Open Access
- 25 March 2026
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 55 (3) , 113-114
Grip strength, sleep status and depression
Frailty screening in community-dwelling older adults offers an opportunity for early identification to mitigate downstream disease burden.
- 25 March 2026
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 55 (3) , 113-114
Open AccessGrip strength, sleep status and depression
Frailty screening in community-dwelling older adults offers an opportunity for early identification to mitigate downstream disease burden.
- Open Access
- 3 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Original Article: Randomised open label cross-over study comparing feasibility of S-patch vs 24 hour holter in Cognitively Impaired and Frail Older People with Falls (Preprint)
BACKGROUND Falls commonly cause injury in older adults and can present with syncope or pre-syncope.Typically cognitively impaired and frail older patients are under represented in research studies and have difficulty tolerating longer periods of ECG monitoring. S-patch is a novel dual lead lightweight device and is well tolerated in older frail and cognitively impaired patients with falls. OBJECTIVE to compare the feasibility, tolerability, and efficacy of the S-Patch—a novel continuous heart rhythm monitoring device which enables up to 72 hours of ECG monitoring with standard 24-hour Holter monitor in cognitive impaired and older adults (≥60 years) presenting with unwitnessed falls, syncope, or near-syncope. METHODS A prospective, single-center, randomized, open-label, cross-over feasibility study was conducted from 8 March 2020 to 28 February 2023. Participants were randomized 1:1 into Group A (GpA), receiving Holter monitoring followed by the S-Patch, or Group B (GpB), receiving the S-Patch first followed by Holter. RESULTS Seventy patients were enrolled, 45.7% of whom had cognitive impairment. GpA participants were older (86.9 vs 82.9 years) and had greater usage of dementia medications (17.1% vs 8.6%). Detection rates for arrhythmia were comparable: Holter detected arrhythmias in 28.6% (GpA) and 48.6% (GpB), while the S-Patch detected 25.7% in both groups. One clinically significant arrhythmia was identified by both devices, resulting in pacemaker implantation. The S-Patch was worn longer in GpB (68.8 vs 62.9 hours, p=0.044) where S-patch was administered first. Frailty was common across groups: CFS 1–3 (17% vs 20%), CFS 4–5 (48.6% vs 54.3%), and CFS 6–9 (34.3% vs 25.7%). Fear of falling was significantly higher among frail patients (p=0.043). CONCLUSIONS The S-Patch was well tolerated and demonstrated comparable performance to the Holter monitor in detecting arrhythmias in older, cognitively impaired patients and provided comparative rate and arrhythmia detection compared to 24 hour Holter CLINICALTRIAL 2019/2960 Comparison of Holter vs S-Patch for Arrhythmia Detection in Older Falls Patient
- 3 August 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessOriginal Article: Randomised open label cross-over study comparing feasibility of S-patch vs 24 hour holter in Cognitively Impaired and Frail Older People with Falls (Preprint)
BACKGROUND Falls commonly cause injury in older adults and can present with syncope or pre-syncope.Typically cognitively impaired and frail older patients are under represented in research studies and have difficulty tolerating longer periods of ECG monitoring. S-patch is a novel dual lead lightweight device and is well tolerated in older frail and cognitively impaired patients with falls. OBJECTIVE to compare the feasibility, tolerability, and efficacy of the S-Patch—a novel continuous heart rhythm monitoring device which enables up to 72 hours of ECG monitoring with standard 24-hour Holter monitor in cognitive impaired and older adults (≥60 years) presenting with unwitnessed falls, syncope, or near-syncope. METHODS A prospective, single-center, randomized, open-label, cross-over feasibility study was conducted from 8 March 2020 to 28 February 2023. Participants were randomized 1:1 into Group A (GpA), receiving Holter monitoring followed by the S-Patch, or Group B (GpB), receiving the S-Patch first followed by Holter. RESULTS Seventy patients were enrolled, 45.7% of whom had cognitive impairment. GpA participants were older (86.9 vs 82.9 years) and had greater usage of dementia medications (17.1% vs 8.6%). Detection rates for arrhythmia were comparable: Holter detected arrhythmias in 28.6% (GpA) and 48.6% (GpB), while the S-Patch detected 25.7% in both groups. One clinically significant arrhythmia was identified by both devices, resulting in pacemaker implantation. The S-Patch was worn longer in GpB (68.8 vs 62.9 hours, p=0.044) where S-patch was administered first. Frailty was common across groups: CFS 1–3 (17% vs 20%), CFS 4–5 (48.6% vs 54.3%), and CFS 6–9 (34.3% vs 25.7%). Fear of falling was significantly higher among frail patients (p=0.043). CONCLUSIONS The S-Patch was well tolerated and demonstrated comparable performance to the Holter monitor in detecting arrhythmias in older, cognitively impaired patients and provided comparative rate and arrhythmia detection compared to 24 hour Holter CLINICALTRIAL 2019/2960 Comparison of Holter vs S-Patch for Arrhythmia Detection in Older Falls Patient
- Open Access
Real-World Effectiveness of Boosting Against Omicron Hospitalization in Older Adults, Stratified by Frailty
Background/Objectives: Older adults with frailty are at-risk of worse outcomes following respiratory-viral-infections such as COVID-19. Data on effectiveness of vaccination/boosting in frail older adults during Omicron is lacking. Methods: National healthcare-claims data and COVID-19 registries were utilized to enroll a cohort of older Singaporeans (≥60 years) as of 1 January 2022, divided into low/intermediate/high-risk for frailty; matching weights were utilized to adjust for sociodemographic differences/vaccination uptake at enrolment across frailty categories. Competing-risk-regression (Fine-Gray) taking death as a competing risk, with matching weights applied, was utilized to compare risks of COVID-19-related hospitalizations and severe COVID-19 across frailty levels (low/intermediate/high-risk), with estimates stratified by booster status. Individuals were followed up until study end-date (20 December 2023). Results: 874,160 older adults were included during Omicron-predominant transmission; ~10% had intermediate/high-frailty-risk. Risk of hospitalization/severe COVID-19 was elevated in those with intermediate/high-frailty-risk up to XBB/JN.1 transmission. Boosting was associated with decreased risk of COVID-19-related hospitalization across all frailty categories in infection-naïve individuals. However, in infection-naïve older adults with high-frailty-risk, while receipt of first boosters was associated with lower risk of COVID-19-hospitalization/severe COVID-19, additional booster doses did not reduce risk. In reinfected older adults, first boosters were still associated with lower hospitalization risk (adjusted-hazards-ratio, aHR = 0.55, 95% CI = 0.33–0.92) among the non-frail, but not in the intermediate/high-frailty-risk minority. Conclusions: First boosters were associated with reduced adverse COVID-19 outcomes across all frailty categories in infection-naïve older adults during Omicron. However, in the high-frailty minority, boosting did not additionally reduce risk in reinfected individuals with hybrid immunity, and beyond the first booster for infection-naïve individuals.
Open AccessReal-World Effectiveness of Boosting Against Omicron Hospitalization in Older Adults, Stratified by Frailty
Background/Objectives: Older adults with frailty are at-risk of worse outcomes following respiratory-viral-infections such as COVID-19. Data on effectiveness of vaccination/boosting in frail older adults during Omicron is lacking. Methods: National healthcare-claims data and COVID-19 registries were utilized to enroll a cohort of older Singaporeans (≥60 years) as of 1 January 2022, divided into low/intermediate/high-risk for frailty; matching weights were utilized to adjust for sociodemographic differences/vaccination uptake at enrolment across frailty categories. Competing-risk-regression (Fine-Gray) taking death as a competing risk, with matching weights applied, was utilized to compare risks of COVID-19-related hospitalizations and severe COVID-19 across frailty levels (low/intermediate/high-risk), with estimates stratified by booster status. Individuals were followed up until study end-date (20 December 2023). Results: 874,160 older adults were included during Omicron-predominant transmission; ~10% had intermediate/high-frailty-risk. Risk of hospitalization/severe COVID-19 was elevated in those with intermediate/high-frailty-risk up to XBB/JN.1 transmission. Boosting was associated with decreased risk of COVID-19-related hospitalization across all frailty categories in infection-naïve individuals. However, in infection-naïve older adults with high-frailty-risk, while receipt of first boosters was associated with lower risk of COVID-19-hospitalization/severe COVID-19, additional booster doses did not reduce risk. In reinfected older adults, first boosters were still associated with lower hospitalization risk (adjusted-hazards-ratio, aHR = 0.55, 95% CI = 0.33–0.92) among the non-frail, but not in the intermediate/high-frailty-risk minority. Conclusions: First boosters were associated with reduced adverse COVID-19 outcomes across all frailty categories in infection-naïve older adults during Omicron. However, in the high-frailty minority, boosting did not additionally reduce risk in reinfected individuals with hybrid immunity, and beyond the first booster for infection-naïve individuals.
- Open Access
- 22 February 2025
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1-10
Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV
Background: Benign Paroxysmal Positional Vertigo (BPPV) is the commonest cause of vertigo in older adults. Due to its high incidence in older adults presenting with falls, vestibular assessment is recommended in the World Guidelines for Falls Prevention. There is a paucity of evidence in well conducted randomised controlled trials (RCTs) to evaluate vitamin D for prevention of BPPV recurrence in relation to falls and function. Aims: Primary outcome: does vitamin D supplementation and dietary interventions in combination with standard care impact falls, fear of falling and function in patients with BPPV. Methods: Post hoc analyses of phase IIa single centre, placebo controlled, double blind RCT evaluating vitamin D supplementation with diet and Canalith Repositioning Procedure (CRP) [Group A] versus diet alone with CRP [Group B] in reducing BPPV recurrence rates and the consequent effects on falls and function. Results: 53 participants were recruited. 14 were vitamin D replete at baseline (Group C) with remaining 39 randomised into Groups A and B. Group A had better 5x sit to stand time and 0.75 fewer clinical BPPV recurrences per one person year (P = 0.035) compared to Group B. 25% of participants who fell reported fear of falling compared to 43% in those without falls in the 12 month follow up. Discussion: Vitamin D supplementation alongside standard BPPV improved 5xchair stand test and reduced BPPV recurrence. Participants without an incident fall during follow up experience fear of falling, prompting further consideration. Conclusion: Vitamin D replacement was associated with fewer BPPV recurrences and improved function assessed with 5x chair stand test.
- 22 February 2025
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1-10
Open AccessFalls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV
Background: Benign Paroxysmal Positional Vertigo (BPPV) is the commonest cause of vertigo in older adults. Due to its high incidence in older adults presenting with falls, vestibular assessment is recommended in the World Guidelines for Falls Prevention. There is a paucity of evidence in well conducted randomised controlled trials (RCTs) to evaluate vitamin D for prevention of BPPV recurrence in relation to falls and function. Aims: Primary outcome: does vitamin D supplementation and dietary interventions in combination with standard care impact falls, fear of falling and function in patients with BPPV. Methods: Post hoc analyses of phase IIa single centre, placebo controlled, double blind RCT evaluating vitamin D supplementation with diet and Canalith Repositioning Procedure (CRP) [Group A] versus diet alone with CRP [Group B] in reducing BPPV recurrence rates and the consequent effects on falls and function. Results: 53 participants were recruited. 14 were vitamin D replete at baseline (Group C) with remaining 39 randomised into Groups A and B. Group A had better 5x sit to stand time and 0.75 fewer clinical BPPV recurrences per one person year (P = 0.035) compared to Group B. 25% of participants who fell reported fear of falling compared to 43% in those without falls in the 12 month follow up. Discussion: Vitamin D supplementation alongside standard BPPV improved 5xchair stand test and reduced BPPV recurrence. Participants without an incident fall during follow up experience fear of falling, prompting further consideration. Conclusion: Vitamin D replacement was associated with fewer BPPV recurrences and improved function assessed with 5x chair stand test.
- Open Access
- 1 December 2024
- Published by Hylonome Publications in Journal of Frailty, Sarcopenia and Falls
- Vol. 9 (4) , 235-248
Modified Hospital Frailty Risk Score (mHFRS) as a Tool to Identify and Predict Outcomes for Hospitalised Older Adults at Risk of Frailty
This study aims to determine whether modified Hospital Frailty Risk Score (mHFRS) can identify frail hospitalised older adults by comparing mHFRS to HFRS and Clinical Frailty Scale (CFS). A retrospective review was undertaken in patients =>65 years hospitalised following an Emergency Department attendance between 1st July 2022 and 31st March 2023. Predictive models were evaluated with correlation and measure of agreement between frailty risk scores, CFS and HFRS, CFS and modified HFRS (mHFRS) using the Spearman’s rank correlation and Cohen’s kappa (κ). Of 3042 patients, CFS categorised 1635 (53.7%) patients as non-frail (CFS 1-4) and 1407 (46.3%) as frail (CFS 5-9,p<0.001). Frail patients were more likely to be female (55.9%), older (81.8 years, SD 8.41 vs 75.3 years, SD 7.20, p<0.001), with longer LOS (52.5% % vs 31.5%, p<0.001), higher 30-day emergency re-admission (18.5% vs 9.9%, p<0.001) and higher mortality at all time points. We could compute mHFRS for 1623 (53.4%) patients, of whom, 37.5% were low risk, 40.5% intermediate risk and 22.1% high frailty risk. mHFRS showed significant correlation with CFS (p<0.001) and HFRS (p<0.001), respectively and achieved comparable association with clinical outcomes. mHFRS was better at identifying non-frail patients and provides a novel, standardised and comparable frailty risk stratification tool for screening older hospitalised patients.
- 1 December 2024
- Published by Hylonome Publications in Journal of Frailty, Sarcopenia and Falls
- Vol. 9 (4) , 235-248
Open AccessModified Hospital Frailty Risk Score (mHFRS) as a Tool to Identify and Predict Outcomes for Hospitalised Older Adults at Risk of Frailty
This study aims to determine whether modified Hospital Frailty Risk Score (mHFRS) can identify frail hospitalised older adults by comparing mHFRS to HFRS and Clinical Frailty Scale (CFS). A retrospective review was undertaken in patients =>65 years hospitalised following an Emergency Department attendance between 1st July 2022 and 31st March 2023. Predictive models were evaluated with correlation and measure of agreement between frailty risk scores, CFS and HFRS, CFS and modified HFRS (mHFRS) using the Spearman’s rank correlation and Cohen’s kappa (κ). Of 3042 patients, CFS categorised 1635 (53.7%) patients as non-frail (CFS 1-4) and 1407 (46.3%) as frail (CFS 5-9,p<0.001). Frail patients were more likely to be female (55.9%), older (81.8 years, SD 8.41 vs 75.3 years, SD 7.20, p<0.001), with longer LOS (52.5% % vs 31.5%, p<0.001), higher 30-day emergency re-admission (18.5% vs 9.9%, p<0.001) and higher mortality at all time points. We could compute mHFRS for 1623 (53.4%) patients, of whom, 37.5% were low risk, 40.5% intermediate risk and 22.1% high frailty risk. mHFRS showed significant correlation with CFS (p<0.001) and HFRS (p<0.001), respectively and achieved comparable association with clinical outcomes. mHFRS was better at identifying non-frail patients and provides a novel, standardised and comparable frailty risk stratification tool for screening older hospitalised patients.
- Open Access
- 28 August 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (1) , 127-136
Randomized Controlled Trial Assessing Vitamin D's Role in Reducing BPPV Recurrence in Older Adults
Objective: To determine if the recurrence rates of BPPV in older adults were lower in the vitamin D‐treated group as compared to placebo groups.Study Design: Double‐blinded randomized control placebo trial.Setting: A single‐centre study.Methods: Double‐blinded randomized controlled trial design with 12 months follow‐up. Vitamin D3 deplete participants were randomized into treatment (Group A) or placebo groups (Group B). Treatment group received 13 weeks of 2000 IU vitamin D3 followed by 1000 IU for the next 13 weeks. Patients who were replete were allocated to a control group (Group C) for observation and follow up. All groups had dietary interventions for vitamin D3 and calcium.Results: Results showed an 87% reduction in recurrence rates of BPPV in the treatment group (Group A), with 0.75 fewer clinical episodes per 1 person‐year as compared to placebo (Group B). Time to first recurrence was also significantly longer in Group A. There was no statistically significant difference between Group A and C in both recurrence rates and dizziness handicap scores.Conclusions: This clinical trial has laid the foundation to expand the investigation of vitamin D as standard of care treatment in BPPV patients in future phase IIb and III studies.Summary: A reduction in BPPV episodes in older adults has implications on fall risk, as dizziness from BPPV may cause falls. With fewer BPPV episodes and longer time to recurrence, seniors may have better postural stability and hence reduced risk of falls.Level of Evidence: 2.
- 28 August 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (1) , 127-136
Open AccessRandomized Controlled Trial Assessing Vitamin D's Role in Reducing BPPV Recurrence in Older Adults
Objective: To determine if the recurrence rates of BPPV in older adults were lower in the vitamin D‐treated group as compared to placebo groups.Study Design: Double‐blinded randomized control placebo trial.Setting: A single‐centre study.Methods: Double‐blinded randomized controlled trial design with 12 months follow‐up. Vitamin D3 deplete participants were randomized into treatment (Group A) or placebo groups (Group B). Treatment group received 13 weeks of 2000 IU vitamin D3 followed by 1000 IU for the next 13 weeks. Patients who were replete were allocated to a control group (Group C) for observation and follow up. All groups had dietary interventions for vitamin D3 and calcium.Results: Results showed an 87% reduction in recurrence rates of BPPV in the treatment group (Group A), with 0.75 fewer clinical episodes per 1 person‐year as compared to placebo (Group B). Time to first recurrence was also significantly longer in Group A. There was no statistically significant difference between Group A and C in both recurrence rates and dizziness handicap scores.Conclusions: This clinical trial has laid the foundation to expand the investigation of vitamin D as standard of care treatment in BPPV patients in future phase IIb and III studies.Summary: A reduction in BPPV episodes in older adults has implications on fall risk, as dizziness from BPPV may cause falls. With fewer BPPV episodes and longer time to recurrence, seniors may have better postural stability and hence reduced risk of falls.Level of Evidence: 2.
- Open Access
- 31 July 2024
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 5 (8) , e508-e509
The effect of frailty in pleural disease
- 31 July 2024
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 5 (8) , e508-e509
Open AccessThe effect of frailty in pleural disease